|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Yoshimoto S, Loo TM, Atarashi K, et al:
Obesity-induced gut microbial metabolite promotes liver cancer
through senescence secretome. Nature. 499:97–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Min L, Ji Y, Bakiri L, et al: Liver cancer
initiation is controlled by AP-1 through SIRT6-dependent inhibition
of survivin. Nat Cell Biol. 14:1203–1211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu X, Fan Z, Kang L, et al: Hepatitis B
virus X protein represses miRNA-148a to enhance tumorigenesis. J
Clin Invest. 123:630–645. 2013.PubMed/NCBI
|
|
5
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu L, Cao Y, Chen C, et al: Sorafenib
blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and
induces tumor cell apoptosis in hepatocellular carcinoma model
PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang SH, Xiong M, Chen XP, Xiao ZY, Zhao
YF and Huang ZY: PJ34, an inhibitor of PARP-1, suppresses cell
growth and enhances the suppressive effects of cisplatin in liver
cancer cells. Oncol Rep. 20:567–572. 2008.PubMed/NCBI
|
|
8
|
Yu S-W, Wang H, Poitras MF, et al:
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by
apoptosis-inducing factor. Science. 297:259–263. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alano CC, Kauppinen TM, Valls AV and
Swanson RA: Minocycline inhibits poly(ADP-ribose) polymerase-1 at
nanomolar concentrations. Proc Natl Acad Sci USA. 103:9685–9690.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yong VW, Wells J, Giuliani F, Casha S,
Power C and Metz LM: The promise of minocycline in neurology.
Lancet Neurol. 3:744–751. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Le CH, Morales A and Trentham DE:
Minocycline in early diffuse scleroderma. Lancet. 352:1755–1756.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu S, Stavrovskaya IG, Drozda M, et al:
Minocycline inhibits cytochrome c release and delays progression of
amyotrophic lateral sclerosis in mice. Nature. 417:74–78. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zink MC, Uhrlaub J, DeWitt J, et al:
Neuroprotective and anti-human immunodeficiency virus activity of
minocycline. JAMA. 293:2003–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stefanova N, Bücke P, Duerr S and Wenning
GK: Multiple system atrophy: an update. Lancet Neurol. 8:1172–1178.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pourgholami MH, Ataie-Kachoie P, Badar S
and Morris DL: Minocycline inhibits malignant ascites of ovarian
cancer through targeting multiple signaling pathways. Gynecol
Oncol. 129:113–119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bouwman P and Jonkers J: The effects of
deregulated DNA damage signalling on cancer chemotherapy response
and resistance. Nat Rev Cancer. 12:587–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fuertes MA, Alonso C and Pérez JM:
Biochemical modulation of Cisplatin mechanisms of action:
enhancement of antitumor activity and circumvention of drug
resistance. Chemical Rev. 103:645–662. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Haubrich WS: Apoptosis. Gastroenterology.
119:18052000. View Article : Google Scholar
|
|
21
|
Lord CJ and Ashworth A: The DNA damage
response and cancer therapy. Nature. 481:287–294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abbas T and Dutta A: p21 in cancer:
intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakayama K, Nagahama H, Minamishima YA, et
al: Targeted disruption of Skp2 results in accumulation of cyclin E
and p27(Kip1), polyploidy and centrosome overduplication. EMBO J.
19:2069–2081. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
le Sage C, Nagel R, Egan DA, et al:
Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222
promotes cancer cell proliferation. EMBO J. 26:3699–3708.
2007.PubMed/NCBI
|
|
25
|
Penninger JM and Kroemer G: Mitochondria,
AIF and caspases - rivaling for cell death execution. Nat Cell
Biol. 5:97–99. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Virag L, Robaszkiewicz A, Vargas JM and
Oliver FJ: Poly(ADP-ribose) signaling in cell death. Mol Aspects
Med. 34:1153–1167. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Günther C, Martini E, Wittkopf N, et al:
Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and
terminal ileitis. Nature. 477:335–339. 2011.PubMed/NCBI
|
|
28
|
Jin Z, Li Y, Pitti R, et al: Cullin3-based
polyubiquitination and p62-dependent aggregation of caspase-8
mediate extrinsic apoptosis signaling. Cell. 137:721–735. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stilmann M, Hinz M, Arslan SÇ, Zimmer A,
Schreiber V and Scheidereit C: A nuclear poly(ADP-Ribose)-dependent
signalosome confers DNA damage-induced IkappaB kinase activation.
Mol Cell. 36:365–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Midorikawa R, Takei Y and Hirokawa N: KIF4
motor regulates activity-dependent neuronal survival by suppressing
PARP-1 enzymatic activity. Cell. 125:371–383. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vondálová Blanárová O, Jelinková I, Szöor
A, et al: Cisplatin and a potent platinum(IV) complex-mediated
enhancement of TRAIL-induced cancer cells killing is associated
with modulation of upstream events in the extrinsic apoptotic
pathway. Carcinogenesis. 32:42–51. 2011.PubMed/NCBI
|
|
32
|
Barton C, Davies D, Balkwill F and Burke
F: Involvement of both intrinsic and extrinsic pathways in
IFN-gamma-induced apoptosis that are enhanced with cisplatin. Eur J
Cancer. 41:1474–1486. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qin LF and Ng IO: Induction of apoptosis
by cisplatin and its effect on cell cycle-related proteins and cell
cycle changes in hepatoma cells. Cancer Lett. 175:27–38. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu FY, Deng YL, Li Y, et al:
Down-regulated KLF17 expression is associated with tumor invasion
and poor prognosis in hepatocellular carcinoma. Med Oncol.
30:4252013. View Article : Google Scholar : PubMed/NCBI
|
